Paraganglioma Clinical Trials

16 recruiting

Paraganglioma Trials at a Glance

25 actively recruiting trials for paraganglioma are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Bethesda, Philadelphia, and St Louis. Lead sponsors running paraganglioma studies include National Cancer Institute (NCI), Peking Union Medical College Hospital, and Felix Beuschlein.

Browse paraganglioma trials by phase

Treatments under study

About Paraganglioma Clinical Trials

Looking for clinical trials for Paraganglioma? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Paraganglioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Paraganglioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting
Phase 1Phase 2

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Kidney CancersHead and Neck TumorsSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 2

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Neuroendocrine TumorsParagangliomaPheochromocytoma+1 more
National Cancer Institute (NCI)130 enrolled1 locationNCT03206060
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Hereditary Breast and Ovarian CancerHodgkin LymphomaAdrenocortical Carcinoma+30 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting
Phase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting
Phase 1Phase 2

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

PheochromocytomaGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive+1 more
National Cancer Institute (NCI)66 enrolled1 locationNCT06427798
Recruiting
Early Phase 1

In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

ParagangliomaPheochromocytoma
Heather Wachtel30 enrolled1 locationNCT05636540
Recruiting
Phase 2

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Advanced Pheochromocytoma and ParagangliomaPCPG
Jazz Pharmaceuticals90 enrolled9 locationsNCT07282587
Recruiting

Institutional Registry of Rare Diseases

ParagangliomaPheochromocytomaAmyloidosis+23 more
Hospital Italiano de Buenos Aires380 enrolled1 locationNCT06573723
Recruiting
Not Applicable

Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma

Pheochromocytoma/Paraganglioma (PPGL)
Peking Union Medical College Hospital40 enrolled1 locationNCT07288931
Recruiting
Phase 4

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

ParagangliomaMeningiomaEsthesioneuroblastoma+4 more
Weill Medical College of Cornell University200 enrolled1 locationNCT04081701
Recruiting

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

ParagangliomaPheochromocytomaKidney Neoplasms+5 more
The University of Texas Health Science Center at San Antonio2,000 enrolled1 locationNCT03160274
Recruiting

Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma

ParagangliomaPheochromocytomaNeuroblastoma
Nanjing First Hospital, Nanjing Medical University30 enrolled1 locationNCT07195500
Recruiting
Phase 2

Ivonescimab in the Treatment of Multiple Advanced Tumors

Urothelial CarcinomaSarcomaKidney Cancer+16 more
Fudan University400 enrolled1 locationNCT06683846
Recruiting

An International Study on Pediatric Patients With Rare Tumors.

MesotheliomaThyroid CarcinomaPleuropulmonary Blastoma+11 more
Azienda Ospedaliera di Padova6,250 enrolled1 locationNCT07072143
Recruiting
Not Applicable

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

ParagangliomaPheochromocytomaGenetic Predisposition+7 more
University of Pennsylvania1,000 enrolled1 locationNCT06377033
Recruiting
Phase 4

The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma

ParagangliomaPheochromocytomaAdrenalectomy; Status+1 more
Seoul National University Hospital24 enrolled1 locationNCT05702944
Recruiting

Hereditary Pheochromocytoma Assessment of Tumour Immunologies

ParagangliomaPheochromocytoma
Radboud University Medical Center200 enrolled1 locationNCT06444607